Calypte Biomedical Issues Update on Informal SEC Inquiry

Calypte Biomedical Issues Update on Informal SEC Inquiry 


PLEASANTON, Calif., July 19  /PRNewswire-FirstCall/ -- Calypte Biomedical
Corporation (OTC:CYPT) (BULLETIN BOARD: CYPT)  announced today that the SEC
Division of Enforcement notified the Company that the informal inquiry that its
staff was conducting has been terminated and that no enforcement action has
been recommended by the Commission at this time.

About Calypte Biomedical:

Calypte Biomedical Corporation, headquartered in Pleasanton, California, is a
public healthcare company dedicated to the development and commercialization of
in vitro diagnostic tests, primarily for the detection of antibodies to Human
Immunodeficiency Virus (HIV), and other sexually transmitted and infectious
diseases. Calypte's currently marketed laboratory- based tests include an
enzyme immunoassay (EIA) HIV-1 antibody screening test and an HIV-1 antibody
western blot supplemental test, the only two FDA- approved HIV-1 antibody tests
for use on urine samples, as well as an FDA- approved serum HIV-1 antibody
western blot supplemental test. Calypte is actively engaged in developing new
test products for the rapid detection of HIV and other infectious diseases. 
Calypte believes that there is a significant need for rapid detection of such
diseases globally to control their proliferation, particularly in
lesser-developed countries, which lack the medical infrastructure to support
laboratory-based testing.  Calypte believes that testing for HIV and other
infectious diseases may make important contributions to public health.

   Company Contact:                       Investor Relations Contact:
   Richard Brounstein, CFO                Tim Clemensen
   [phone]                         Rubenstein Investor Relations
   email:          Phone: [phone]
                                          Email: 

DATASOURCE: Calypte Biomedical Corporation



CONTACT:  Richard Brounstein, CFO of Calypte Biomedical Corporation,

[phone], or ; or Tim Clemensen of Rubenstein

Investor Relations, [phone], or , for

Calypte Biomedical Corporation 



Web site:  http://www.calypte.com/ 

Copyright